Seminars in Nuclear Medicine
Volume 32, Issue 1 , Pages 35-46 , January 2002

Whole-body FDG-PET imaging in the management of patients with cancer

  • Roland Hustinx

      Affiliations

    • Division of Nuclear Medicine, Centre hospitalier universitaire, Liège, Belgium
    • Division of Nuclear Medicine, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Québec, Canada
    • Division of Nuclear Medicine Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • ,
  • François Bénard

      Affiliations

    • Division of Nuclear Medicine, Centre hospitalier universitaire, Liège, Belgium
    • Division of Nuclear Medicine, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Québec, Canada
    • Division of Nuclear Medicine Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • ,
  • Abass Alavi

      Affiliations

    • Division of Nuclear Medicine, Centre hospitalier universitaire, Liège, Belgium
    • Division of Nuclear Medicine, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Québec, Canada
    • Division of Nuclear Medicine Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Corresponding Author InformationAddress reprint requests to Abass Alavi, MD, Division of Nuclear Medicine, Hospital of the University of Pennsylvania, 110 Donner Bldg, 3400 Spruce St, Philadelphia, PA.

References 

  1. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol. 1998;16:2113–2125
  2. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA. 2001;285:914–924
  3. Dewan NA, Reeb SD, Gupta NC, et al. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest. 1995;108:441–446
  4. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology. 1999;213:530–536
  5. Weng E, Tran L, Rege S, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol. 2000;23:47–52
  6. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med. 1998;25:1495–1501
  7. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest. 2000;117:773–778
  8. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998;25:1244–1247
  9. [see comments] Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:1357–1360
  10. Hustinx R, Paulus P, Jacquet N, et al. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol. 1998;9:397–401
  11. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. 1994;344:1265–1266
  12. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998;66:886–893
  13. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803–809
  14. Saunders CA, Dussek JE, O'Doherty MJ, et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999;67:790–797
  15. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest. 1997;112:1480–1486
  16. Hicks RJ, Kalff V, Mac Manus MP, et al. Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) provides high impact and powerful prognostic stratification in staging new diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596–1604
  17. Hicks RJ, Kalff V, Mac Manus MP, et al. The utility of F-18 FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med. 2001;42:1605–1613
  18. [see comments] Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med. 1996;37:1428–1436
  19. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis. Ann Thorac Surg. 1998;66:1876–1885
  20. Kosuda S, Ichihara K, Watanabe M, et al. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. Chest. 2000;117:346–353
  21. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: Priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000;27:1598–1609
  22. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–261
  23. Farrell MA, McAdams HP, Herndon JE, et al. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology. 2000;215:886–890
  24. Patz EF, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol. 2000;174:769–774
  25. Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001;91:302–310
  26. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91:889–899
  27. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997;203:795–800
  28. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: Detection with FDG PET versus CT. Radiology. 1998;206:475–481
  29. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol. 1998;9:1117–1122
  30. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun. 1999;20:13–20
  31. Klose T, Leidl R, Buchmann I, et al. Primary staging of lymphomas: Cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med. 2000;27:1457–1464
  32. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603–609
  33. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340–3346
  34. Najjar F, Hustinx R, Jerusalem G, et al. Positron emission tomography for staging low-grade non Hodgkin's lymphomas. Cancer Biother Radiopharm. 2001;16:297–304
  35. Shah N, Hoskin P, McMillan A, et al. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br J Radiol. 2000;73:482–487
  36. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999;10:1181–1184
  37. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429–433
  38. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol. 2001;19:414–419
  39. Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055–1063
  40. de Wit M, Bumann D, Beyer W, et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997;8:57–60
  41. Mikhaeel NG, Timothy AR, Hain SF, et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 2000;11(suppl 1):147–150
  42. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464–4471
  43. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18f-fdg uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000;85:613–618
  44. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?. Eur J Nucl Med. 2000;27:1564–1578
  45. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–1189
  46. Staib L, Schirrmeister H, Reske SN, et al. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?. Am J Surg. 2000;180:1–5
  47. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000;43:759–770
  48. Meta J, Seltzer M, Schiepers C, et al. Impact of (18)f-fdg pet on managing patients with colorectal cancer: The referring physician's perspective. J Nucl Med. 2001;42:586–590
  49. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–946
  50. Jarnagin WR, Fong Y, Ky A, et al. Liver resection for metastatic colorectal cancer: Assessing the risk of occult irresectable disease. J Am Coll Surg. 1999;188:33–42
  51. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21–26
  52. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996;131:703–707
  53. Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999;178:282–287
  54. Strasberg SM, Dehdashti F, Siegel BA, et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study. Ann Surg. 2001;233:293–299
  55. Brennan MF. PET scanning in malignancy: Infant, adolescent or mature citizen?. Ann Surg. 2001;233:320–321
  56. Park KC, Schwimmer J, Shepherd JE, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg. 2001;233:310–319
  57. [see comments] Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319–323
  58. Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer. The utility of positron emission tomography (PET). Eur J Cancer. 2001;37:862–869
  59. Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 1997;64:770–777
  60. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000;25:882–887
  61. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64:765–769
  62. Rankin SC, Taylor H, Cook GJ, et al. Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma. Clin Radiol. 1998;53:659–665
  63. Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:417–424
  64. [see comments] Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–3210
  65. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg. 2001;233:300–309
  66. Flamen P, Lerut A, Van Cutsem E, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg. 2000;120:1085–1092
  67. [see comments] Stollfuss JC, Glatting G, Friess H, et al. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation. Radiology. 1995;195:339–344
  68. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US. Radiology. 1995;195:345–352
  69. Imdahl A, Nitzsche E, Krautmann F, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg. 1999;86:194–199
  70. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784–1791
  71. Sendler A, Avril N, Helmberger H, et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: Diagnostic limitations. World J Surg. 2000;24:1121–1129
  72. [see comments] Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998;25:259–264
  73. Diederichs CG, Staib L, Vogel J, et al. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas. 2000;20:109–116
  74. Frohlich A, Diederichs CG, Staib L, et al. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med. 1999;40:250–255
  75. Nakamoto Y, Higashi T, Sakahara H, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol. 1999;54:248–252
  76. Rose DM, Delbeke D, Beauchamp RD, et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999;229:729–738
  77. Maisey NR, Webb A, Flux GD, et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study. Br J Cancer. 2000;83:287–293
  78. Higashi T, Sakahara H, Torizuka T, et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med. 1999;40:1424–1433
  79. Mijnhout GS, Hoekstra OS, van Tulder MW, et al. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530–1542
  80. Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Quart J Nucl Med. 2000;44:153–167
  81. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674–2678
  82. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999;17:1508–1515
  83. Damian DL, Fulham MJ, Thompson E, et al. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325–329
  84. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med. 2000;25:48–51
  85. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019–1025
  86. [see comments] Rinne D, Baum RP, Hor G, et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer. 1998;82:1664–1671
  87. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer. 1994;73:3047–3058
  88. Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol. 1998;27:342–347
  89. Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998;25:1255–1260
  90. McGuirt WF, Williams DW, Keyes JW, et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope. 1995;105:373–375
  91. Braams JW, Pruim J, Freling NJ, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med. 1995;36:211–216
  92. Benchao M, Lehmann W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol (Stockh). 1996;116:332–335
  93. Kresnik E, Mikosch P, Gallowitsch HJ, et al. Evaluation of head and neck cancer with 18F-FDG PET: A comparison with conventional methods. Eur J Nucl Med. 2001;28:816–821
  94. [see comments] Greven KM, Williams DW, Keyes JW, et al. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?. Can J Sci Am. 1997;3:353–357
  95. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology. 1996;200:135–141
  96. Lapela M, Grenman R, Kurki T, et al. Head and neck cancer: Detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology. 1995;197:205–211
  97. Lonneux M, Lawson G, Ide C, et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope. 2000;110:1493–1497
  98. Farber LA, Benard F, Machtay M, et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope. 1999;109:970–975
  99. Li P, Zhuang H, Mozley PD, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med. 2001;26:131–135
  100. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer. 1998;82:1160–1166
  101. Lassen U, Daugaard G, Eigtved A, et al. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Can. 1999;35:1076–1082
  102. Greven KM, Keyes JW, Williams DW, et al. Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer. 1999;86:114–118
  103. Aassar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors. Radiology. 1999;210:177–181
  104. Bohuslavizki KH, Klutmann S, Kroger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med. 2000;41:816–822
  105. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23:312–319
  106. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study. Eur J Nucl Med. 1999;26:1547–1552
  107. Dietlein M, Scheidhauer K, Voth E, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342–1348
  108. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291–2302
  109. Shiga T, Tsukamoto E, Nakada K, et al. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med. 2001;42:414–419
  110. Yeo JS, Chung JK, So Y, et al. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck. 2001;23:94–103
  111. Altenvoerde G, Lerch H, Kuwert T, et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg. 1998;383:160–163
  112. Jadvar H, McDougall IR, Segall GM. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 1998;19:547–554
  113. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med. 1999;40:986–992
  114. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg. 2000;179:457–461
  115. Alnafisi NS, Driedger AA, Coates G, et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med. 2000;41:1010–1015
  116. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71–76
  117. Adler LP, Crowe JP, al-Kaisi NK, et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology. 1993;187:743–750
  118. Noh DY, Yun IJ, Kim JS, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg. 1998;22:223–228
  119. Palmedo H, Bender H, Grunwald F, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med. 1997;24:1138–1145
  120. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr. 1993;17:582–589
  121. Scheidhauer K, Scharl A, Pietrzyk U, et al. Qualitative [18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability. Eur J Nucl Med. 1996;23:618–623
  122. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol. 2000;18:3495–3502
  123. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9–16
  124. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med. 1998;39:4–8
  125. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg. 1998;228:220–227
  126. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst. 1996;88:1204–1209
  127. Bender H, Kirst J, Palmedo H, et al. Value of 18fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 1997;17:1687–1692
  128. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures. Eur J Nucl Med. 2001;28:351–358
  129. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–2389
  130. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431–435
  131. Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience. Radiology. 1999;210:807–814
  132. Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?. J Clin Oncol. 1995;13:1470–1477
  133. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol. 1993;11:2101–2111
  134. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689–1695
  135. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676–1688
  136. Balk E, Lau J. PET scans and technology assessment: Deja vu?. JAMA. 2001;285:936–937

* Supported in part by the Canadian Institutes of Health Research under the clinician-scientist award program (F.B.).

PII: S0001-2998(02)80038-1

doi: 10.1053/snuc.2002.29272

Seminars in Nuclear Medicine
Volume 32, Issue 1 , Pages 35-46 , January 2002

Article Tools